Q-omics provides the consensus-scored NAB2 profile across patient tissues and cancer cell-line models. NAB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAB2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NAB2 protein abundance shows 22,704 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where NAB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAB2 survival associations across molecular data types. NAB2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAB2 RNA expression–survival associations across cancer types. High NAB2 expression shows unfavorable associations in KIRC, ACC, KIRP, LGG, UVM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NAB2 RNA expression.
This table summarizes NAB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NAB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAB2 shows lower tumor expression in KICH, UCEC and BLCA and higher tumor expression in THCA, HNSC and COAD. The THCA box plot shows higher NAB2 RNA expression in tumor versus normal tissue (log2 FC = +2.372, t-test p < 0.001).
This table shows molecular features associated with NAB2 in patient tissues and cancer cell lines. In patient samples, NAB2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
